Discovery of new chemical classes of synthetic ligands that suppress neuroinflammatory responses
Tóm tắt
We used a chemical genomics approach that includes follow up in parallel syntheses to discover a new class of compounds that selectively suppress glial activation. While the mechanism of action remains to be determined, available data and the experimental approach for discovery indicate that the mechanism includes inhibition of gene regulating protein kinases. Specifically, the increased production of IL-1β and iNOS in response to various activating stimuli, including Aβ1-42, is suppressed while the production of potentially beneficial responses, such as ApoE production, is not inhibited. The increased production of COX-2 and p38 MAPK activation are also not altered, demonstrating the novel nature of potential therapeutic targets compared to currently available drugs. The chemical scaffold is 3-aminopyridazine (3-AP). This is an attractive scaffold because of its potential for diversification by established, facile chemistries and the prior use of a 3-AP scaffold in other central nervous system targeted therapeutics. Therefore, the potential bioavailability of 3-AP derivatives and the demonstrated cellular selectivity demand that future research address the potential efficacy of selective 3-AP derivatives in animal models of disease.
Tài liệu tham khảo
Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G. M., et al. (2000) Inflammation and Alzheimer’s disease. Neurobiol. Aging 21, 383–421.
Badger A. M., Bradbeer J. N., Votta B., Lee J. C., Adams J. L., and Griswold D. E. (1996) Pharmacological profile of SB203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Therapeut. 279, 1453–1461.
Glicksman M. A., Chiu A. Y., Dionne C. A., Harty M., Kaneko M., Murakata C., et al. (1998) CEP-1347/KT7515 prevents motor neuronal programmed cell death and injury-induced dedifferentiation in vivo. J. Neurobiol. 35, 361–378.
Griffin W. S. T., Sheng J. G., Royston M. C., Gentleman S. M., McKenzie J. E., Graham D. I., et al. (1998) Glial-neuronal interactions in Alzheimer’s disease: the potential role of a “cytokine cycle” in disease progression. Brain Pathol. 8, 65–72.
Guo L., Sawkar A., Zasadzki M., Watterson D. M., and Van Eldik L. J. (2001) Activation of glia from different brain regions and modulation by new classes of ligands that downregulate glial activation. Neurobiol. Aging 22, 975–981.
Heinisch G. and Frank H. (1990) Pharmacologically active pyridazine derivatives. Part 1. Prog. Med. Chem. 27, 1–49.
Heinisch G. and Frank H. (1992) Pharmacologically active pyridazine derivatives. Part 2. Prog. Med. Chem. 29, 141–183.
Lee J. C., Laydon J. T., McDonnell P. C., Galagher T. F., Kumar S., Green D., et al. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739–746.
Lim G. P., Yang F., Chu T., Chen P., Beech W., Teter B., et al. (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J. Neurosci. 20, 5709–5714.
Maroney A. C., Finn J. P., Bozyczko-Coyne D., O’Kane T. M., Neff N. T., Tolkovsky A. M., et al. (1999) CEP-1347 (KT7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC12 cells from death evoked by three distinct insults. J. Neurochem. 73, 1901–1912.
Melikian G., Schlewer J. P., Chambon P., and Wermuth C. G. (1992) Condensation of muscimol or thiomuscimol with aminopyridazines yields GABA-A antagonists. J. Med. Chem. 35, 4092–4097.
Mirzoeva S., Koppal T., Petrova T. V., Lukas T. J., Watterson D. M., and Van Eldik L. J. (1999) Screening in a cell based assay for inhibitors of microglial nitric oxide production reveals calmodulin regulated protein kinases as potential drug discovery targets. Brain Res. 844, 126–134.
Mirzoeva S., Sawker A., Zasadzki M., et al. (2002) Discovery of a 3-amino-6-phenyl-pyridazine derivative as a new synthetic antineuroinflammatory compound. J. Med. Chem. 45, 563–566.
Pirvola U., Xing-Qun L., Virkkala J., Saarma M., Murakata C., Camoratto A. M., et al. (2000) Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation. J. Neurosci. 20, 43–50.
Saporito M. S., Brown E. M., Miller M. S., and Carswell S. (1999) CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J. Pharmacol. Exp. Therapeut. 288, 421–427.
Saturnino C., Abarghaz M., Schmitt M., Wermuth C.-G., and Bourguignon J.-J. (1995) Heterocyclic amidines. I-A one-step synthesis of new α-substituted imidazolylphenylacetic acids. Heterocycles 41, 1491–1501.
Van Eldik L. J. (2001) Glia and Alzheimer’s disease. Neurochem. Int. 39, 329–331.
Velentza A. V., Schumacher A. M., Weiss C., Egli M., and Watterson D. M. (2001) A protein kinase associated with apoptosis and tumor suppression: structure, activity and discovery of peptide substrates. J. Biol. Chem. 276, 38956–38965.
Watterson D. M., Mirzoeva S., Guo L., Whyte A., Bourguignon J.-J., Hibert M., et al. (2001) Ligand modulation of glial activation: cell permeable, small molecule inhibitors of serine-threonine protein kinases can block induction of interleukin-1β and nitric oxide synthase II. Neurochem. Int. 39, 459–468.